CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Medium term efficacy and safety of adalimumab therapy in patients with Crohn's disease. national data from Hungary
DOI 10.1055/s-0030-1254751
Bibliografische Angaben
Nachweis in CareLit
Autor:innenZ Czegledi, P Miheller, T Molnar, L Lakatos, A Vincze, K Palatka, B Gasztonyi, A Salamon, G Horvath, T Szamosi, Z Tulassay, M Papp, L Kiss, J Papp, P Lakatos
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe05/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background/Aims: Adalimumab is a fully human monoclonal antibody targeting tumor necrosis factor with proven efficacy in the treatment of Crohn's disease in clinical trials. In the present study our aim was to investigate the short and medium term efficacy and side effects during induction and maintenance adalimumab therapy in patients with Crohn's disease in specialized centers approved for biological therapy in Hu…
Zitieren
Zitierempfehlung
Z Czegledi, P Miheller, T Molnar, L Lakatos, A Vincze, K Palatka, B Gasztonyi, A Salamon, G Horvath, T Szamosi, Z Tulassay, M Papp, L Kiss, J Papp, P Lakatos (2010) Medium term efficacy and safety of adalimumab therapy in patients with Crohn's disease. national data from Hungary. Zeitschrift für Gastroenterologie (05). https://doi.org/10.1055/s-0030-1254751
Mit CareLit weiterarbeiten